Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Reporting Period: The filing announces financial results and operational updates for the three and nine months ended September 30, 2025.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) containing the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It only confirms that an update on operations for the period ended September 30, 2025, was issued via a press release.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on November 12, 2025, providing an update on operations for the three and nine months ended September 30, 2025.
Other Events: The Company updated its corporate presentation slide deck, filed as Exhibit 99.2.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the period ended September 30, 2025.
- Examine Exhibit 99.2 (Corporate Presentation) for updated operational milestones and strategic outlook.
- Verify the Company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in the 8-K cover text.
- Confirm any new guidance or timeline updates for clinical trials mentioned in the referenced press release.